Document is current
Any future updates will be listed below
-
Authors
Bejar, Nada https://orcid.org/0000-0002-0980-5951
Tat, Trinh T. https://orcid.org/0000-0002-6419-8007
Kiss, Daniel L. https://orcid.org/0000-0001-5033-7160
- License Information
-
More Information
Article History
Accepted: 25 January 2022
First Online: 2 April 2022
Declarations
:
: Dr. Kiss runs an externally funded lab (American Heart Association [20CDA35310329], and NIH [R35GM137819-02, -02S1, -02S2]) that is actively designing and testing different candidate RNA therapeutics, including some with possible applications in cardiovascular disease. All authors anticipate seeking appropriate intellectual property protection for promising candidates that emerge from the lab’s work. Dr. Kiss has patents planned for circular RNA therapeutics and an inducible stable HUVEC cell line. Further, Dr. Kiss serves as a consultant for the RNA Core at the Houston Methodist Research Institute. In addition, Dr. Kiss reports private stock for BioLife Solutions Inc. Dr. Bejar is named as a co-inventor on a provisional patent filing for a candidate RNA therapeutic (EFS ID: 44070986 pending). Dr. Tat has a patent planned for circular RNA therapeutics.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
